National Cancer Institute; Notice of Closed Meeting, 70170 [2012-28370]
Download as PDF
70170
Federal Register / Vol. 77, No. 226 / Friday, November 23, 2012 / Notices
Agenda: The agenda items for the
December meeting will include, but are not
limited to: updates from the Division of
Vaccine Injury Compensation (DVIC);
Department of Justice (DOJ); National
Vaccine Program Office (NVPO);
Immunization Safety Office (Centers for
Disease Control and Prevention); National
Institute of Allergy and Infectious Diseases
(National Institutes of Health); and Center for
Biologics, Evaluation and Research (Food
and Drug Administration). A draft agenda
and additional meeting materials will be
posted on the ACCV Web site (https://www.
hrsa.gov/vaccinecompensation/accv.htm)
prior to the meeting. Agenda items are
subject to change as priorities dictate.
Public Comment: Persons interested in
attending the meeting in person or providing
an oral presentation should submit a written
request along with a copy of their
presentation to: Annie Herzog, DVIC,
Healthcare Systems Bureau (HSB), Health
Resources and Services Administration
(HRSA), Room 11C–26, 5600 Fishers Lane,
Rockville, Maryland 20857 or email:
aherzog@hrsa.gov. Requests should contain
the name, address, telephone number, email
address, and any business or professional
affiliation of the person desiring to make an
oral presentation. Groups having similar
interests are requested to combine their
comments and present them through a single
representative. The allocation of time may be
adjusted to accommodate the level of
expressed interest. DVIC will notify each
presenter by email, mail, or telephone of
their assigned presentation time. Persons
who do not file an advance request for a
presentation, but desire to make an oral
statement, may announce it at the time of the
public comment period. Public participation
and ability to comment will be limited to
space and time as it permits.
For Further Information Contact: Anyone
requiring information regarding the ACCV
should contact Annie Herzog, DVIC, HSB,
HRSA, Room 11C–26, 5600 Fishers Lane,
Rockville, MD 20857; telephone (301) 443–
6593; or email: aherzog@hrsa.gov.
Dated: November 16, 2012.
Bahar Niakan,
Director, Division of Policy and Information
Coordination.
[FR Doc. 2012–28377 Filed 11–21–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel,
December 3, 2012, 8:30 a.m. to
December 4, 2012, 5:00 p.m., which was
published in the Federal Register on
November 1, 2012, 77 FR Pg. 66854–
66855.
VerDate Mar<15>2010
17:03 Nov 21, 2012
Jkt 229001
The meeting will be held November
27–28, 2012 at 8:30 a.m. and will end
at 5:00 p.m. The meeting location
remains the same. The meeting is closed
to the public.
Dated: November 16, 2012
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28368 Filed 11–21–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Experimental Therapeutics Program (NExT).
Date: December 12, 2012.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health,
Neuroscience Building, 6001 Executive
Boulevard, Conference Room A1 & A2,
Bethesda, MD 20852.
Contact Person: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, MD 20892,
(301) 496–4291, mroczkoskib@mail.nih.gov.
Joseph Tomaszewski, Ph.D., Executive
Secretary, Development Experimental
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44,
Bethesda, MD 20892, (301) 496–6711,
tomaszej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 16, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–28370 Filed 11–21–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel NCI
Experimental Therapeutics Program (NExT).
Date: December 12, 2012.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health,
Neuroscience Building, 6001 Executive
E:\FR\FM\23NON1.SGM
23NON1
Agencies
[Federal Register Volume 77, Number 226 (Friday, November 23, 2012)]
[Notices]
[Page 70170]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-28370]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2); notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; NCI Experimental Therapeutics Program (NExT).
Date: December 12, 2012.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, Neuroscience Building,
6001 Executive Boulevard, Conference Room A1 & A2, Bethesda, MD
20852.
Contact Person: Barbara Mroczkowski, Ph.D., Executive Secretary,
Discovery Experimental Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892,
(301) 496-4291, mroczkoskib@mail.nih.gov.
Joseph Tomaszewski, Ph.D., Executive Secretary, Development
Experimental Therapeutics Program, National Cancer Institute, NIH,
31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496-6711,
tomaszej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 16, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-28370 Filed 11-21-12; 8:45 am]
BILLING CODE 4140-01-P